辅助酪氨酸激酶抑制剂改善ABL类融合儿童急性淋巴细胞白血病预后
在UKALL2011研究中,对诱导后MRD≥1%的患者筛查ABL类融合,阳性者(12%)接受辅助TKI治疗。
要点
- ABL类融合儿童ALL标准化疗复发风险高,但对TKI敏感。
- UKALL2011中诱导后MRD≥1%者筛查,12%阳性并接受辅助TKI。
核心结论
- 在首次缓解期接受辅助TKI治疗的ABL类融合儿童ALL患者,与未接受TKI的等效患者相比,复发/难治风险显著降低。
研究设计与样本
- 基于UKALL2011研究,对诱导后MRD≥1%的患者进行ABL类融合筛查,阳性患者(12%)接受辅助TKI;因干预在UKALL2011期间启动,并非所有合格患者均前瞻性筛查,通过回顾性筛查合格患者比较接受与未接受TKI者的结局。
关键数值与推荐
- 诱导后MRD≥1%的患者中ABL类融合阳性率为12%。
临床怎么用
- 对诱导后MRD≥1%的儿童ALL患者应筛查ABL类融合,阳性者在首次缓解期考虑辅助TKI治疗以降低复发/难治风险。
局限性
- 因干预启动时并非所有合格患者均前瞻性筛查,部分患者为回顾性筛查,可能引入选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
引用
- Moorman AV, Schwab C, Winterman E, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol. 2020. PMID: 32926422. doi:10.1111/bjh.17093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。